Predictive models for response and survival in patients treated with anti-PD-1 monotherapy or with anti-PD-1 and ipilimumab combination: editorial commentary.
作者信息
Rotte Anand
机构信息
Clinical and Regulatory Affairs, Arcellx Inc., Redwood City, CA, USA.
出版信息
Ann Transl Med. 2023 Mar 15;11(5):227. doi: 10.21037/atm-22-6564. Epub 2023 Jan 27.
Abstract
摘要
相似文献
1
Predictive models for response and survival in patients treated with anti-PD-1 monotherapy or with anti-PD-1 and ipilimumab combination: editorial commentary.抗PD-1单药治疗或抗PD-1与伊匹木单抗联合治疗患者的反应和生存预测模型：编辑评论
Ann Transl Med. 2023 Mar 15;11(5):227. doi: 10.21037/atm-22-6564. Epub 2023 Jan 27.
2
Ipilimumab alone or ipilimumab plus anti-PD-1 therapy in patients with metastatic melanoma resistant to anti-PD-(L)1 monotherapy: a multicentre, retrospective, cohort study.伊匹木单抗单药治疗或伊匹木单抗联合抗PD-1治疗转移性黑色素瘤患者对抗PD-(L)1单药治疗耐药：一项多中心、回顾性队列研究。
Lancet Oncol. 2021 Jun;22(6):836-847. doi: 10.1016/S1470-2045(21)00097-8. Epub 2021 May 11.
3
Efficacy and safety of anti-PD-1 and anti-PD-1 combined with anti-CTLA-4 immunotherapy to advanced melanoma: A systematic review and meta-analysis of randomized controlled trials.抗程序性死亡蛋白1（anti-PD-1）及抗PD-1联合抗细胞毒性T淋巴细胞相关蛋白4（anti-CTLA-4）免疫疗法用于晚期黑色素瘤的疗效与安全性：一项随机对照试验的系统评价与Meta分析
Medicine (Baltimore). 2017 Jun;96(26):e7325. doi: 10.1097/MD.0000000000007325.
4
Ipilimumab alone or in combination with nivolumab after progression on anti-PD-1 therapy in advanced melanoma.在晚期黑色素瘤患者抗PD-1治疗进展后，使用伊匹单抗单药或与纳武单抗联合治疗。
Eur J Cancer. 2017 Apr;75:47-55. doi: 10.1016/j.ejca.2017.01.009. Epub 2017 Feb 17.
5
Comparative effectiveness of second-line ipilimumab vs. nivolumab in combination with ipilimumab in patients with advanced melanoma who received frontline anti-PD-1 antibodies.二线伊匹单抗与纳武单抗联合伊匹单抗在接受一线抗PD-1抗体治疗的晚期黑色素瘤患者中的疗效比较。
J Oncol Pharm Pract. 2021 Apr;27(3):555-559. doi: 10.1177/1078155220924719. Epub 2020 May 19.
6
The impact of BRAF mutation status on clinical outcomes with anti-PD-1 monotherapy versus combination ipilimumab/nivolumab in treatment-naïve advanced stage melanoma.BRAF 突变状态对初治晚期黑色素瘤患者接受抗 PD-1 单药治疗与 ipilimumab/nivolumab 联合治疗的临床结局的影响。
Pigment Cell Melanoma Res. 2021 May;34(3):629-640. doi: 10.1111/pcmr.12944. Epub 2020 Nov 22.
7
Peripheral blood clinical laboratory variables associated with outcomes following combination nivolumab and ipilimumab immunotherapy in melanoma.外周血临床实验室变量与黑色素瘤患者接受纳武利尤单抗和伊匹单抗联合免疫治疗后的结局相关。
Cancer Med. 2018 Mar;7(3):690-697. doi: 10.1002/cam4.1356. Epub 2018 Feb 22.
8
Association of Anti-Programmed Cell Death 1 Antibody Treatment With Risk of Recurrence of Toxic Effects After Immune-Related Adverse Events of Ipilimumab in Patients With Metastatic Melanoma.抗程序性细胞死亡蛋白 1 抗体治疗与转移性黑色素瘤患者接受伊匹单抗免疫相关不良反应后毒性作用复发风险的相关性。
JAMA Dermatol. 2020 Sep 1;156(9):982-986. doi: 10.1001/jamadermatol.2020.2149.
9
Efficacy of PD-1-based immunotherapy after radiologic progression on targeted therapy in stage IV melanoma.在晚期黑色素瘤的靶向治疗中，影像学进展后 PD-1 免疫治疗的疗效。
Eur J Cancer. 2019 Jul;116:207-215. doi: 10.1016/j.ejca.2019.05.015. Epub 2019 Jun 15.
10
Systemic Analysis and Review of Nivolumab-ipilimumab Combination as a Rescue Strategy for Renal Cell Carcinoma After Treatment With Anti-PD-1/PD-L1 Therapy.纳武利尤单抗联合伊匹木单抗作为抗 PD-1/PD-L1 治疗后肾细胞癌挽救策略的系统分析和综述。
Clin Genitourin Cancer. 2021 Apr;19(2):95-102. doi: 10.1016/j.clgc.2020.10.004. Epub 2020 Oct 15.
引用本文的文献
1
Editorial: Emerging learnings in cell therapy: novel binding domains, universal CAR-T cells, and more.社论：细胞疗法的新进展：新型结合域、通用型嵌合抗原受体T细胞等等。
Front Oncol. 2024 Apr 15;14:1404376. doi: 10.3389/fonc.2024.1404376. eCollection 2024.
2
Development of Cell and Gene Therapies for Clinical Use in the US and EU: Summary of Regulatory Guidelines.细胞和基因治疗在美国和欧盟的临床应用开发：监管指南摘要。
Curr Gene Ther. 2024;25(1):10-21. doi: 10.2174/0115665232306205240419091414.
3
Postoperative adjuvant immunotherapy for high-risk hepatocellular carcinoma patients.高危肝细胞癌患者的术后辅助免疫治疗
Front Oncol. 2023 Dec 15;13:1289916. doi: 10.3389/fonc.2023.1289916. eCollection 2023.
4
Immune checkpoints are predominantly co-expressed by clonally expanded CD4FoxP3 intratumoral T-cells in primary human cancers.免疫检查点主要由原发性人类癌症中克隆扩增的 CD4FoxP3 肿瘤内 T 细胞共表达。
J Exp Clin Cancer Res. 2023 Dec 6;42(1):333. doi: 10.1186/s13046-023-02897-6.
5
Current state and challenges of emerging biomarkers for immunotherapy in hepatocellular carcinoma (Review).肝细胞癌免疫治疗新兴生物标志物的现状与挑战（综述）
Exp Ther Med. 2023 Nov 3;26(6):586. doi: 10.3892/etm.2023.12285. eCollection 2023 Dec.
本文引用的文献
1
PD-1/PD-L1 checkpoint inhibitors in advanced hepatocellular carcinoma immunotherapy.PD-1/PD-L1 检查点抑制剂在晚期肝细胞癌免疫治疗中的应用。
Front Immunol. 2022 Dec 19;13:1070961. doi: 10.3389/fimmu.2022.1070961. eCollection 2022.
2
Cross-study safety analysis of risk factors in CAR T cell clinical trials: An FDA database pilot project.嵌合抗原受体T细胞（CAR T）临床试验中风险因素的跨研究安全性分析：一项美国食品药品监督管理局（FDA）数据库试点项目
Mol Ther Oncolytics. 2022 Oct 20;27:182-194. doi: 10.1016/j.omto.2022.10.006. eCollection 2022 Dec 15.
3
Clinical Models to Define Response and Survival With Anti-PD-1 Antibodies Alone or Combined With Ipilimumab in Metastatic Melanoma.用于定义单独使用抗PD-1抗体或联合伊匹单抗治疗转移性黑色素瘤的反应和生存情况的临床模型
J Clin Oncol. 2022 Apr 1;40(10):1068-1080. doi: 10.1200/JCO.21.01701. Epub 2022 Feb 10.
4
Pharmacology-based ranking of anti-cancer drugs to guide clinical development of cancer immunotherapy combinations.基于药理学的抗癌药物排名，以指导癌症免疫治疗联合用药的临床开发。
J Exp Clin Cancer Res. 2021 Oct 1;40(1):311. doi: 10.1186/s13046-021-02111-5.
5
Targeting TIGIT for Immunotherapy of Cancer: Update on Clinical Development.靶向TIGIT用于癌症免疫治疗：临床进展更新
Biomedicines. 2021 Sep 21;9(9):1277. doi: 10.3390/biomedicines9091277.
6
Immune Checkpoint Inhibitors in Colorectal Cancer: Challenges and Future Prospects.结直肠癌中的免疫检查点抑制剂：挑战与未来前景
Biomedicines. 2021 Aug 24;9(9):1075. doi: 10.3390/biomedicines9091075.
7
Advances in drug development for hepatocellular carcinoma: clinical trials and potential therapeutic targets.肝细胞癌药物研发进展：临床试验与潜在治疗靶点。
J Exp Clin Cancer Res. 2021 May 18;40(1):172. doi: 10.1186/s13046-021-01968-w.
8
Effect of Systemic Corticosteroid Therapy on the Efficacy and Safety of Nivolumab in the Treatment of Non-Small-Cell Lung Cancer.系统性皮质类固醇治疗对非小细胞肺癌纳武利尤单抗治疗疗效和安全性的影响。
Cancer Control. 2021 Jan-Dec;28:1073274820985790. doi: 10.1177/1073274820985790.
9
Combination of CTLA-4 and PD-1 blockers for treatment of cancer.CTLA-4 和 PD-1 抑制剂联合治疗癌症。
J Exp Clin Cancer Res. 2019 Jun 13;38(1):255. doi: 10.1186/s13046-019-1259-z.
10
Monoclonal Antibodies for the Treatment of Melanoma: Present and Future Strategies.用于治疗黑色素瘤的单克隆抗体：当前与未来策略
Methods Mol Biol. 2019;1904:83-108. doi: 10.1007/978-1-4939-8958-4_4.
Zotero 插件